Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3- (2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N, N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist

Journal of Pharmacology and Experimental Therapeutics

Volumn 300, Issue 3, 2002, Pages 1122-1130

  Serradeil Le Gal, Claudine ^a,b,c,d   Wagnon, Jean ^a,b,c,d   Simiand, Jacques ^a,b,c,d   Griebel, G U Y ^a,b,c,d   Lacour, Colette ^a,b,c,d   Guillon, Gilles ^a,b,c,d   Barberis, Claude ^a,b,c,d   Brossard, Gabrielle ^a,b,c,d   Soubrié, Philippe ^a,b,c,d   Nisato, Dino ^a,b,c,d   Pascal, Marc ^a,b,c,d   Pruss, Rebecca ^a,b,c,d   Scatton, Bernard ^a,b,c,d   Maffrand, Jean Pierre ^a,b,c,d   Fur, Gérard L E ^a,b,c,d  

^a Exploratory Research Department   (France)

^b Central Nervous System Research Department   (France)

^c SANOFI   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; 1 [5 CHLORO 1 [(2,4 DIMETHOXYPHENYL)SULFONYL] 3 (2 METHOXYPHENYL) 2 OXO 2,3 DIHYDRO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINE CARBOXAMIDE; ARGIPRESSIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; OXYTOCIN RECEPTOR; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY NEUROSIS; ARTICLE; BINDING COMPETITION; BODY WATER; CHO CELL; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DRUG EFFECT; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; IMMOBILIZATION STRESS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; TRANQUILIZING ACTIVITY; WATER LOSS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTI-ANXIETY AGENTS; ARGININE VASOPRESSIN; CATTLE; CELL MEMBRANE; CELLS, CULTURED; CHO CELLS; CRICETINAE; DEHYDRATION; HUMANS; HYPOTHALAMUS; KINETICS; MALE; MORPHOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOPRESSIN; SPIRO COMPOUNDS; STRESS, PSYCHOLOGICAL;

EID: 18244378573     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.300.3.1122     Document Type: Article

References (41)

1. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: Implications for stress adaptation
2. Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor
3. Molecular pharmacology of AVP and OT receptors and therapeutic potential
4. In vivo and in vitro effects of argininevasopressin receptor antagonists on the hypothalamic-pituitary-adrenal axis in the rat
5. A new method for rapid screening of minor tranquillizers in mice
6. Comparison of behavioral effects after single and repeated administrations of four benzodiazepines in three mice behavioral models
7. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
8. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
9. Repeated stress enhances vasopressin synthesis in corticotropin releasing factor neurons in the paraventricular nucleus
10. Cloning and characterization of the human V3 pituitary vasopressin receptor
11. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours
12. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease
13. Vasopressin receptor localization and neuronal responsiveness in the rat brain
14. Properties of rat anterior pituitary vasopressin receptors: Relation to adenylate cyclase and the effect of corticotropin-releasing factor
15. Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
16. A new generation of Ca2+ indicators with greatly improved fluorescence properties
17. Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice
18. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: Anatomical support for its involvement in the central effects of vasopressin
19. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety
20. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models
21. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats
22. Effect of AVP and oxytocin on insulin release: Involvement of V1b receptors
23. Stress-induced secretion of adrenocorticotropin in rats is inhibited by administration of antisera to ovine corticotropin-releasing factor and vasopressin
24. Molecular biology of vasopressin receptors
25. Extrapituitary expression of the rat V1b vasopressin receptor gene
26. Characterization of a vasopressin V1b receptor knockout mouse
27. Expression of all known vasopressin receptor subtypes by small cell tumors implies a multifaceted role for this neuropeptide
28. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues
29. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat
30. Interaction of corticotropin-releasing factor and arginine vasopressin on adrenocorticotropin secretion in vivo
31. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells
32. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist
33. 3H]-SR 121463
34. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors
35. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor
36. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist
37. Molecular pharmacology of human vasopressin receptors
38. The human V3 pituitary vasopressin receptor: Ligand binding profile and density-dependent signaling pathways
39. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain
40. Gene and cDNA cloning and characterization of the mouse V3/V1b pituitary vasopressin receptor
41. Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas